ACADIA Pharmaceuticals (ACAD) Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ACAD Community Fair Values
Create NarrativeSee what 108 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$28.75
FV
2.6% overvalued intrinsic discount10.02%
Revenue growth p.a.
87
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
ACADIA Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.50 |
| 52 Week High | US$30.96 |
| 52 Week Low | US$19.69 |
| Beta | 0.85 |
| 1 Month Change | 18.76% |
| 3 Month Change | 39.81% |
| 1 Year Change | 14.61% |
| 3 Year Change | 3.15% |
| 5 Year Change | 72.41% |
| Change since IPO | 340.30% |
Recent News & Updates
Narrative Update • Aug 19
ACAD: RADIANT Phase 2 Alzheimer’s Psychosis Data Will Drive Upside Potential
Analysts have increased their average price targets for ACADIA Pharmaceuticals by a few dollars per share, with higher fair value estimates at $47.18 that reflect increased confidence in remlifanserin and Daybue following recent research updates. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals points to a broadly constructive stance from bullish analysts, with a series of upward price target revisions clustered around key catalysts for Daybue and remlifanserin.Analysis Article • Aug 08
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) just released its quarterly report and things are looking bullish. It was...
Narrative Update • Aug 05
ACAD: Future Upside Will Hinge On Alzheimer Psychosis Remlifanserin Data
ACADIA Pharmaceuticals' analyst fair value estimate has been adjusted to $33.25 from $31.80 as analysts factor in stronger Daybue traction, higher long term profit margin assumptions, and the upcoming Phase 2 remlifanserin readout as key supports for higher price targets across the Street. Analyst Commentary Recent research on ACADIA Pharmaceuticals points to a generally constructive tone, with many firms lifting price targets and focusing on execution around Daybue, Nuplazid and the upcoming remlifanserin data.Recent updates
Narrative Update • Aug 19
ACAD: RADIANT Phase 2 Alzheimer’s Psychosis Data Will Drive Upside Potential
Analysts have increased their average price targets for ACADIA Pharmaceuticals by a few dollars per share, with higher fair value estimates at $47.18 that reflect increased confidence in remlifanserin and Daybue following recent research updates. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals points to a broadly constructive stance from bullish analysts, with a series of upward price target revisions clustered around key catalysts for Daybue and remlifanserin.Analysis Article • Aug 08
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) just released its quarterly report and things are looking bullish. It was...Narrative Update • Aug 05
ACAD: Future Upside Will Hinge On Alzheimer Psychosis Remlifanserin Data
ACADIA Pharmaceuticals' analyst fair value estimate has been adjusted to $33.25 from $31.80 as analysts factor in stronger Daybue traction, higher long term profit margin assumptions, and the upcoming Phase 2 remlifanserin readout as key supports for higher price targets across the Street. Analyst Commentary Recent research on ACADIA Pharmaceuticals points to a generally constructive tone, with many firms lifting price targets and focusing on execution around Daybue, Nuplazid and the upcoming remlifanserin data.Seeking Alpha • Jul 27
Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readout
Summary Acadia Pharmaceuticals Inc. ended July on a high note. The top line results from the Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis are expected in August-October 2026. Acadia expects its 2026 revenue will be $1.22-$1.28 billion, representing about 16.5% YoY growth. Meanwhile, the average price target for Acadia is $32.8 [from $17 to $45], which implies an upside of about 32.1% from its current stock price. As a result, in my view, Acadia's risk/reward is attractive. Read the full article on Seeking Alpha
Narrative Update • Jul 22
ACAD: Alzheimer’s Psychosis Data Will Test High-Risk Remlifanserin Story
Analysts have raised their average price targets on ACADIA Pharmaceuticals by a few dollars per share into the mid $30s, citing expectations for stronger Daybue and Nuplazid trends, as well as updated views on pipeline assets such as remlifanserin and trofinetide, following recent positive CHMP opinions and study designs. Analyst Commentary Recent research on ACADIA Pharmaceuticals points to a mix of optimism around product momentum and caution around execution and drug development risk.Narrative Update • Jun 17
ACAD: Buy Upgrade And Guidance Reaffirmation Will Drive Upside From Pullback
ACADIA Pharmaceuticals' analyst price target has been trimmed by $1, as analysts recalibrate their models around slightly different long term growth, profitability, and discount rate assumptions reflected in recent research updates. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals shows a mix of caution and optimism, with the modest price target trim sitting alongside more constructive views from bullish analysts who see room for the stock to recover from recent weakness.Narrative Update • Jun 02
ACAD: Rett And Alzheimer’s Psychosis Milestones Will Shape Balanced Risk Reward
Analysts have nudged their price expectations for ACADIA Pharmaceuticals higher, with the updated fair value estimate moving from about $19.64 to $19.75 per share as they refine assumptions around growth, margins, and future P/E multiples following recent target changes and rating updates on the stock. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals reflects a mix of optimism and caution, with some firms lifting price targets and others trimming expectations or flagging risks.Narrative Update • May 09
ACAD: Remlifanserin Alzheimer’s Psychosis Readout Will Drive Upside From Undervalued Levels
Analysts recently adjusted their fair value estimate for ACADIA Pharmaceuticals slightly lower to $43.55 from $43.97, reflecting updated assumptions for revenue growth, profitability, and future P/E. This revision also incorporates mixed but generally constructive Street price target updates in the $26 to $37 range, along with several fresh Buy and Outperform ratings.Narrative Update • Apr 23
ACAD: Execution Risk Around Rett Syndrome Setback Will Limit Future Upside
Analysts trimmed the fair value estimate for ACADIA Pharmaceuticals slightly to $19.64 from $19.73, as modestly higher discount rate assumptions offset slightly stronger projected revenue growth and profitability. They maintained a supportive stance following a mix of recent price target increases and reductions across the Street.Narrative Update • Apr 08
ACAD: Future Upside Will Depend On Alzheimer Psychosis Trial Outcomes
The fair value estimate for ACADIA Pharmaceuticals has increased slightly to $31.80, as analysts incorporate updated revenue growth assumptions, mixed adjustments to price targets across firms, and ongoing expectations for contributions from Nuplazid, Daybue, and the broader pipeline. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals shows a mix of optimism and caution, with several firms revising price targets after earnings updates, guidance, and pipeline commentary.Narrative Update • Mar 24
ACAD: Remlifanserin Alzheimer’s Psychosis Data Will Drive Upside From Undervalued Levels
ACADIA Pharmaceuticals' updated analyst price target moves from $37 to about $44, with analysts pointing to refreshed models that reflect recent guidance, ongoing commercial momentum in Nuplazid and Daybue, and growing attention on the remlifanserin Phase 2 program in Alzheimer's disease psychosis. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals clusters around refreshed models, updated sales assumptions for Nuplazid and Daybue, and rising interest in the remlifanserin program in Alzheimer's disease psychosis.Narrative Update • Mar 10
ACAD: Trofinetide EU Setback And Execution Risks Will Likely Restrain Upside
ACADIA Pharmaceuticals' updated analyst price target reflects a modest reset in fair value to $19.73 from $20.26, as analysts balance recent target revisions across the Street with refreshed assumptions for growth, margins, and future P/E levels. Analyst Commentary Across recent research updates, views on ACADIA are mixed, with several large firms expressing confidence in the commercial trajectory of Nuplazid and Daybue, while others are more measured and focused on execution risks and how much of the current pipeline is already reflected in the share price.Narrative Update • Feb 23
ACAD: Pipeline And Execution Risks Will Likely Cap Upside Despite Renewed Optimism
ACADIA Pharmaceuticals' updated fair value estimate has edged up from $19.65 to $20.26 per share, reflecting analysts' higher price targets tied to confidence in Nuplazid and Daybue, as well as underappreciated upside from the remlifanserin pipeline asset. Analyst Commentary Recent research views on ACADIA are mixed, with some firms pointing to upside tied to Nuplazid, Daybue, and the remlifanserin program, while others are more guarded.Narrative Update • Feb 09
ACAD: Higher P/E Assumptions Will Rely On Successful Rett Syndrome Expansion
Analysts have nudged their fair value estimate for ACADIA Pharmaceuticals higher by about $0.47 per share, reflecting recent price target revisions and updated assumptions around revenue growth, profitability, and future P/E multiples. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals has been active, with multiple firms revising price targets and updating their views on the company.Narrative Update • Jan 25
ACAD: Execution Risk And Sector Capital Pressures Will Likely Constrain Upside
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing updated assumptions around revenue growth, profitability and future P/E expectations, alongside a generally cautious but constructive view on Biotech, with potential M&A activity helping to support the sector. Analyst Commentary While the updated US$40 target signals constructive sentiment on ACADIA Pharmaceuticals, recent commentary still carries a cautious tone around how the story plays out over time.Narrative Update • Jan 11
ACAD: Higher P/E Assumptions Will Support Upside If Pipeline Milestones Deliver
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing a refreshed view on fair value, updated discount rate assumptions, and adjusted expectations for revenue growth, profit margin, and future P/E multiples. Analyst Commentary Recent commentary around ACADIA Pharmaceuticals reflects a mix of optimism on potential value creation and caution around sector level capital trends.Narrative Update • Dec 26
ACAD: Expanded Neuroscience Pipeline Will Drive Upside From Undervalued Levels
Analysts have modestly increased their price target on ACADIA Pharmaceuticals from 35.00 dollars to 37.00 dollars. They cited slightly stronger long term revenue growth, improved profit margin expectations, a marginally lower discount rate, and a higher projected future price to earnings multiple.Narrative Update • Dec 12
ACAD: Upcoming Neuropsychiatric Data Expected To Drive Upside Despite Recent Setback
Analysts have trimmed their price target on ACADIA Pharmaceuticals by $5 to $35 per share. This reflects a modestly higher discount rate and lower long term profit expectations, despite slightly stronger projected revenue growth and reassurance that the ACP-101 failure has only a small impact on overall valuation.Analysis Article • Nov 13
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings
Even though ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) posted strong earnings recently, the stock hasn't reacted in a...Analysis Article • Nov 09
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) came out with its quarterly results last week, and we wanted to see how the...Narrative Update • Sep 26
Global Outreach And Pipeline Programs Will Expand CNS Markets
ACADIA Pharmaceuticals’ consensus price target was revised downward to $29.32 as the Phase 3 failure of ACP-101 in Prader-Willi syndrome modestly reduced pipeline value, though the impact is seen as limited given low expectations and resilience in the core business. Analyst Commentary Bearish analysts cite the Phase 3 failure of ACP-101 in Prader-Willi syndrome (PWS), which missed its primary endpoint, leading to lowered price targets based on reduced near-term pipeline value.Narrative Update • Sep 04
Global Outreach And Pipeline Programs Will Expand CNS Markets
Analysts maintained their price target for ACADIA Pharmaceuticals at $29.95 as strong Daybue growth, favorable Nuplazid patent rulings, and strategic R&D focus offset near-term competitive and pipeline uncertainties. Analyst Commentary Bullish analysts are raising price targets citing strong Daybue growth in Q2, but note further acceleration is needed for material upside.Seeking Alpha • Feb 13
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'
Summary Acadia Pharmaceuticals has shown significant financial improvement, reporting a profit of $82.7m in 2024, compared to a loss of $(107m) in 2023. The company's revenue growth is driven by NUPLAZID and DAYBUE, with 2024 revenue projections of $600m-$610m and $340m-$350m respectively, and overall revenues forecast to exceed $1bn in '25. Acadia's promising pipeline, including ACP-204 and ACP-101, and successful marketing campaigns suggest strong future growth potential. Given the company's profitability, robust pipeline, and undervaluation compared to peers, I am upgrading Acadia from "Sell" to "Buy". Read the full article on Seeking AlphaSeeking Alpha • Nov 27
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
Summary NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growth could come from two late-stage assets known as ACP-101 for hyperphagia of PWS and ACP-204 for Alzheimer's Disease Psychosis. Company entered into a worldwide license agreement with Saniona to develop and commercialize SAN711 for the treatment of patients with Essential Tremor; Phase 2 study to be initiated in 2026. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Summary Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth. An updated analysis around ACAD stock follows in the paragraphs below. Read the full article on Seeking AlphaShareholder Returns
| ACAD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.5% | 7.1% | -1.5% |
| 1Y | 14.6% | 45.3% | 17.8% |
Return vs Industry: ACAD underperformed the US Biotechs industry which returned 45.3% over the past year.
Return vs Market: ACAD underperformed the US Market which returned 17.8% over the past year.
Price Volatility
| ACAD volatility | |
|---|---|
| ACAD Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACAD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACAD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 797 | Catherine Owen Adams | www.acadia.com |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer’s disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington’s disease and is in phase I trial.
ACADIA Pharmaceuticals Inc. Fundamentals Summary
| ACAD fundamental statistics | |
|---|---|
| Market cap | US$5.08b |
| Earnings (TTM) | US$380.48m |
| Revenue (TTM) | US$1.14b |
13.4x
P/E Ratio4.5x
P/S RatioIs ACAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACAD income statement (TTM) | |
|---|---|
| Revenue | US$1.14b |
| Cost of Revenue | US$431.99m |
| Gross Profit | US$706.66m |
| Other Expenses | US$326.17m |
| Earnings | US$380.48m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.21 |
| Gross Margin | 62.06% |
| Net Profit Margin | 33.42% |
| Debt/Equity Ratio | 0% |
How did ACAD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/23 06:56 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ACADIA Pharmaceuticals Inc. is covered by 38 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Jack Allen | Baird |
| Joel Beatty | Baird |